COVID-OUT Media Resources
Parsemus Foundation Press Information
About the Parsemus Foundation
The Parsemus Foundation works to create meaningful improvements in human and animal health and welfare by advancing innovative and neglected medical research. The foundation supports proof-of-concept studies and then seeks to raise awareness of results, to ensure that they change treatment practice rather than disappear into the scientific literature. Many of the studies the foundation supports involve low-cost approaches that are not under patent, and are thus unlikely to be pursued by pharmaceutical companies due to limited profit potential.
COVID-OUT Clinical Trial Results Announced!
The key finding: if started within 4 days of COVID symptoms, the widely available diabetes drug metformin reduced serious outcomes by more than half.
Background: The COVID-OUT clinical trial was aimed at understanding if safe, commonly available medications may treat COVID-19 symptoms and those of long COVID. The study examined the medications metformin, ivermectin, and fluvoxamine, which are known to decrease inflammatory proteins (cytokines) in the body. They also appear to possibly stop the proteins inside cells that help viruses reproduce and spread. This rigorous randomized, controlled clinical trial was conducted by the University of Minnesota under the direction of Dr. Carolyn Bramante.
Funders: The Parsemus Foundation provided pilot funding and enrollment support to the University of Minnesota. Additional major funders include the University of Minnesota Clinical Translational Science Institute, the Rainwater Foundation, FastGrants, and UnitedHealth Group Research and Development.
- Parsemus Foundation Press Release (English, Spanish, Portuguese)
- University of Minnesota COVID-OUT Press Release
- Parsemus Foundation COVID-OUT webpage
- New England Journal of Medicine Publication
- KARE 11 News coverage
- Northwestern Medicine release
- University of Colorado release
- Parsemus Foundation video files English, Spanish, Portuguese (below)